BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34907389)

  • 1. COVID-19 timeline of events.
    Webster P
    Nat Med; 2021 Dec; 27(12):2054-2055. PubMed ID: 34907389
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
    Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
    J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
    Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
    Crickx E; Moulis G; Ebbo M; Terriou L; Briantais A; Languille L; Limal N; Guillet S; Michel M; Mahevas M; Godeau B
    Br J Haematol; 2021 Dec; 195(5):703-705. PubMed ID: 34467525
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis.
    Bilotta C; Perrone G; Adelfio V; Spatola GF; Uzzo ML; Argo A; Zerbo S
    Front Immunol; 2021; 12():729251. PubMed ID: 34912330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
    Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC;
    Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
    Chan WY; Howells L; Wilson W; Sanchez E; Ainley L; Chavda SJ; Dowling E; Correia N; Lecat CSY; McMillan A; Wisniowski B; Mahmood S; Papanikolaou X; Lee L; Sive J; Kyriakou C; Wechalekar A; Popat R; Rabin N; Nastouli E; Yong KL; Xu K
    Br J Haematol; 2022 Feb; 196(3):e21-e26. PubMed ID: 34632575
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    Roberge G; Carrier M
    Clin Appl Thromb Hemost; 2022; 28():10760296221086283. PubMed ID: 35275495
    [No Abstract]   [Full Text] [Related]  

  • 12. Report of two cases of minimal change disease following vaccination for COVID -19.
    Baskaran K; Cohen AWS; Weerasinghe N; Vilayur E
    Nephrology (Carlton); 2022 Jan; 27(1):111-112. PubMed ID: 34779088
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 Vaccine Combination Was Superior in Real-world Study.
    Abbasi J
    JAMA; 2021 Dec; 326(22):2250. PubMed ID: 34905046
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune Thrombocytopenia (ITP): Relapse Versus de novo After COVID-19 Vaccination.
    Al-Ahmad M; Al Rasheed M; Shalaby N; Rodriguez-Bouza T; Altourah L
    Clin Appl Thromb Hemost; 2022; 28():10760296211073920. PubMed ID: 35108113
    [No Abstract]   [Full Text] [Related]  

  • 15. Isolated thrombosis after COVID-19 vaccination: case series.
    Al-Ahmad M; Al Rasheed M; Altourah L; Rodriguez-Bouza T; Shalaby N
    Int J Hematol; 2022 Feb; 115(2):153-157. PubMed ID: 34993889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Fox TA; Kirkwood AA; Enfield L; O'Reilly M; Arulogun S; D'Sa S; O'Nions J; Kavi J; Vitsaras E; Townsend W; Burns SO; Gohil SH; Cwynarski K; Thomson KJ; Noursadeghi M; Heyderman RS; Rampling T; Ardeshna KM; McCoy LE; Morris EC
    Br J Haematol; 2021 Dec; 195(5):706-709. PubMed ID: 34545952
    [No Abstract]   [Full Text] [Related]  

  • 18. Fast Development of High-Quality Vaccines in a Pandemic.
    Pischel L; Yildirim I; Omer SB
    Chest; 2021 Jul; 160(1):e1-e3. PubMed ID: 33848535
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Patone M; Handunnetthi L; Saatci D; Pan J; Katikireddi SV; Razvi S; Hunt D; Mei XW; Dixon S; Zaccardi F; Khunti K; Watkinson P; Coupland CAC; Doidge J; Harrison DA; Ravanan R; Sheikh A; Robertson C; Hippisley-Cox J
    Nat Med; 2021 Dec; 27(12):2144-2153. PubMed ID: 34697502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study.
    Kim JW; Kim YG; Park YC; Choi S; Lee S; Min HJ; Kim MJ
    J Korean Med Sci; 2022 Feb; 37(7):e58. PubMed ID: 35191234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.